Drug Profile
IDM 1
Alternative Names: IDM-1; MAK/IDM-1; Osidem; Osidem-1™; Osidem-2Latest Information Update: 22 Feb 2010
Price :
$50
*
At a glance
- Originator IDM S.A.
- Developer IDM S.A.; IDM-Biotech; Lady Davis Institute for Medical Research
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; IgG receptor antagonists; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ovarian cancer
Most Recent Events
- 08 Apr 2005 Suspended - Phase-III for Ovarian cancer in Australia (Intraperitoneal)
- 08 Apr 2005 Suspended - Phase-III for Ovarian cancer in Canada (Intraperitoneal)
- 08 Apr 2005 Suspended - Phase-III for Ovarian cancer in Europe (Intraperitoneal)